Over the last 40 years SJCRH has maintained a highly-productive and distinguished record in the development of new treatments of childhood cancers (Figure 1). The continued success of this ongoing effort is made possible by the conduct of innovative early phase clinical trials by collaborating clinical and laboratory research groups within the Cancer Center. Historically, these clinical trials have focused on the pharmacokinetic properties, clinical efficacy and toxicity of drugs, since most were believed to act through non-specific cytotoxic mechanisms. Recent advances in understanding of the biology of cancer have led to the development of drugs that target specific molecules within cancer cells, e.g. inhibitors of tyrosine kinases. Therefore, over the last 5 years the proportion of the clinical trials conducted within the Cancer Center that test molecular targeted therapies has increased to between 50 and 75% (Figure 1). The proper evaluation of the anticancer properties of this new class of drugs requires assessment of the expression and activity of the drug target within patient tissues alongside measures of drug pharmacokinetics, efficacy and toxicity. Therefore, to ensure that SJCRH remains at the forefront of anticancer drug development it has established the MCTC that provides: expert advice on the incorporation of molecular assays of drug target expression and activity within clinical trials;systems for the efficient and proper collection and handling of clinical samples;expert laboratory facilities for sensitive and specific analysis of drug targets in these clinical materials;and support for the appropriate analysis and interpretation of all data generated by these assays. In this manner the MCTC Shared Resource responds directly to recommendations made by the National Cancer Institute's (NCI) Clinical Trials Committee (response to the Clinical Trials Program Review Armitage Committee), and to section 7 of templates provided for both Phase I and II trial design by the Cancer Therapeutics Evaluation Program (CTEP) at NCI.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA021765-34W1
Application #
8738019
Study Section
Special Emphasis Panel (ZCA1-RTRB-Z)
Project Start
2012-03-01
Project End
2014-02-28
Budget Start
2012-03-01
Budget End
2013-02-28
Support Year
34
Fiscal Year
2013
Total Cost
$801
Indirect Cost
$343
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Wu, Jianrong (2015) Power and sample size for randomized phase III survival trials under the Weibull model. J Biopharm Stat 25:16-28
Serinagaoglu, Yelda; Paré, Joshua; Giovannini, Marco et al. (2015) Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development. Dev Biol 398:97-109
Kimberg, Cara I; Klosky, James L; Zhang, Nan et al. (2015) Predictors of health care utilization in adult survivors of childhood cancer exposed to central nervous system-directed therapy. Cancer 121:774-82
Bhojwani, Deepa; McCarville, Mary B; Choi, John K et al. (2015) The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma. Br J Haematol 168:845-53
Chamdine, Omar; Gaur, Aditya H; Broniscer, Alberto (2015) Effective treatment of cerebral mucormycosis associated with brain surgery. Pediatr Infect Dis J 34:542-3
Karol, Seth E; Coustan-Smith, Elaine; Cao, Xueyuan et al. (2015) Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy. Br J Haematol 168:94-101
Chan, W K; Suwannasaen, D; Throm, R E et al. (2015) Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activity. Leukemia 29:387-95
Gawade, Prasad L; Oeffinger, Kevin C; Sklar, Charles A et al. (2015) Lifestyle, distress, and pregnancy outcomes in the Childhood Cancer Survivor Study cohort. Am J Obstet Gynecol 212:47.e1-10
Momani, Tha'er G; Mandrell, Belinda N; Gattuso, Jami S et al. (2015) Children's perspective on health-related quality of life during active treatment for acute lymphoblastic leukemia: an advanced content analysis approach. Cancer Nurs 38:49-58
Dodd, K; Nance, S; Quezada, M et al. (2015) Tumor-derived inducible heat-shock protein 70 (HSP70) is an essential component of anti-tumor immunity. Oncogene 34:1312-22

Showing the most recent 10 out of 5513 publications